If approved, sasanlimab would be the first PD-1 inhibitor, in combination with BCG, to significantly prolong event-free survival in this patient population
The study also met all secondary endpoints with a reduction in severity of VMS at weeks 4 and 12, a reduction in frequency of VMS at week 1 as well as improvements in sleep disturbances and menopause related quality of life
The President said that there is a need to spread more and more awareness regarding the causes, diagnosis and treatment of cancer
Mankind Pharma will have exclusive rights to register, import, market, sell and distribute sintilimab in India
In the US, the compassionate use approvals are provided by FDA in the form of individual patient-specific expanded-access IND
Harnessing advanced data analysis for early detection, prevention and better outcomes
IBRANCE is the first CDK4/6 inhibitor to show benefit in a large Phase 3 trial in first-line HR+, HER2+ metastatic breast cancer, in combination with anti-HER2 and endocrine therapy
First and only PARP inhibitor to improve overall survival in early breast cancer
Vepdegestrant in combination with abemaciclib demonstrated encouraging clinical activity (clinical benefit rate
CLL is one of the most common leukemias among adults affecting more than 200,000 people in the US
Subscribe To Our Newsletter & Stay Updated
